Spiros Jamas - 01 Jan 2022 Form 3/A - Amendment Insider Report for Entera Bio Ltd. (ENTX)

Role
Chief Executive Officer
Signature
/s/ Dana Yaacov-Garbeli, Attorney-in-fact
Issuer symbol
ENTX
Transactions as of
01 Jan 2022
Net transactions value
$0
Form type
3/A - Amendment
Filing time
24 Jan 2022, 15:13:30 UTC
Date Of Original Report
20 Jan 2022
Next filing
24 Jan 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ENTX Stock Option (right to buy) 01 Jan 2022 Ordinary Shares, par value NIS 0.0000769 per share 1,314,218 $1.24 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This Form 3 amendment is being filled to correct the original Form 3 filed on January 20, 2022. The original Form 3 inadvertently marked the Reporting Person as a director of Entera Bio Ltd. The Reporting Person is only an officer of Entera Bio Ltd. as reflected herein.

Remarks:

See Exhibit 24.1 - Power of Attorney